1.Pigmentation by transdermal fentanyl patch
Hiroaki Shibahara ; Ei Sekoguchi ; Nagayuki Takeshita ; Shingo Suzuki ; Miho Morimoto ; Sachiko Inaguma ; Yoko Mori ; Sumiyo Kudo ; Yumi Ota ; Mika Nishimura ; Natsuko Uematsu ; Eri Imai ; Daisaku Nishimura
Palliative Care Research 2013;8(1):523-528
Introduction: There has been no case report in which hyperpigmentation developed on the skin area where a transdermal fentanyl patch was applied in a patient. Case report: A 43-year-old man with recurrence of postoperative rectal cancer was treated by cetuximab plus irinotecan and panitumumab plus FOLFIRI. For cancer pain, transdermal fentanyl patch (Fentos®) was administered, and radiation from behind was performed. Hyperpigmentation then appeared on the chest and the abdominal skin sites where the patches were applied. The hyperpigmentation nearly disappeared four months after the fentanyl patch was discontinued. Discussion: The cause of the pigmentation was possibly due to post inflammatory hyperpigmentation secondary to contact dermatitis. It was desirable to conduct patch test and skin biopsy for making an accurate diagnosis. Conclusion: We should pay a careful attention to hyperpigmentation of the skin where a transdermal fentanyl patch is applied.
Result Analysis
Print
Save
E-mail